ZM 447439

Cat. No. 2458

ZM 447439 C29H31N5O4 [331771-20-1]

Price and Availability

For ZM 447439 pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: N-[4-[[6-Methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]benzamide

Biological Activity

Novel, selective ATP-competitive inhibitor of Aurora B kinase in vitro (IC50 values are 50, 250 and 1000 nM for Aurora B, C and A kinases respectively). Selective over a range of other kinases including cdk1 and PLK1 (IC50 > 10 μM). Inhibits cell division and displays selective toxicity towards proliferating tumor cells versus non-dividing cells.

Licensing Information

Sold with the permission of AstraZeneca UK Ltd.

Technical Data

M.Wt:
513.59
Formula:
C29H31N5O4
Solubility:
Soluble to 100 mM in DMSO
Purity:
>98 %
Storage:
Store at -20°C
CAS No:
331771-20-1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Product Datasheet / Safety Datasheet

Certificate of Analysis / Product Datasheet
Select another batch:

References are publications that support the products' biological activity.

Girdler et al (2006) Validating Aurora B as an anti-cancer drug target. J.Cell Sci. 119 3664. PMID: 16912073.

Jung et al (2006) Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J.Med.Chem. 49 955. PMID: 16451062.

Ditchfield et al (2003) Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J.Cell Biol. 161 267. PMID: 12719470.

If you know of a relevant reference for ZM 447439 please let us know.

Citations are publications that use Tocris products. Selected citations for ZM 447439 include:

Kim and Yu (2015) Multiple assembly mechanisms anchor the KMN spindle checkpoint platform at human mitotic kinetochores. J Cell Biol 208 181. PMID: 25601404.

Platani et al (2015) Mio depletion links mTOR regulation to Aurora A and Plk1 activation at mitotic centrosomes. J Cell Biol 210 45. PMID: 26124292.

Tauchman et al (2015) Stable kinetochore-microtubule attachment is sufficient to silence the spindle assembly checkpoint in human cells. J Cell Sci 6 10036. PMID: 26620470.

Balboula and Schindler (2014) Selective disruption of aurora C kinase reveals distinct functions from aurora B kinase during meiosis in mouse oocytes. PLoS Genet 10 e1004194. PMID: 24586209.

Mäki-Jouppila et al (2014) Centmitor-1, a novel acridinyl-acetohydrazide, possesses similar molecular interaction field and antimitotic cellular phenotype as rigosertib, on 01910.Na. Nat Commun 13 1054. PMID: 24748653.

Ferreira et al (2013) Aurora B spatially regulates EB3 phosphorylation to coordinate daughter cell adhesion with cytokinesis. J Cell Biol 201 709. PMID: 23712260.

Floyd et al (2013) Spatiotemporal organization of Aurora-B by APC/CCdh1 after mitosis coordinates cell spreading through FHOD1. Cell Cycle 126 2845. PMID: 23613471.

Wang et al (2012) Haspin inhibitors reveal centromeric functions of Aurora B in chromosome segregation. J Cell Biol 199 251. PMID: 23071152.

Foley et al (2011) Formation of stable attachments between kinetochores and microtubules depends on the B56-PP2A phosphatase. Nat Cell Biol 13 1265. PMID: 21874008.

Kasuboski et al (2011) Zwint-1 is a novel Aurora B substrate required for the assembly of a dynein-binding platform on kinetochores. Mol Biol Cell 22 3318. PMID: 21775627.

Tardáguila et al (2011) Aurora kinase B activity is modulated by thyroid hormone during transcriptional activation of pituitary genes. Mol Endocrinol 25 385. PMID: 21239609.

Yuan et al (2011) Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. Am J Pathol 179 2091. PMID: 21839059.

Bassett et al (2010) Epigenetic centromere specification directs aurora B accumulation but is insufficient to efficiently correct mitotic errors. Mol Cancer Ther 190 177. PMID: 20643881.

Bastos and Barr (2010) Plk1 negatively regulates Cep55 recruitment to the midbody to ensure orderly abscission. J Cell Biol 191 751. PMID: 21079244.

Jelluma et al (2010) Release of Mps1 from kinetochores is crucial for timely anaphase onset. Cell Cycle 191 281. PMID: 20937696.

Manchado et al (2010) Targeting mitotic exit leads to tumor regression in vivo: Modulation by Cdk1, Mastl, and the PP2A/B55α,δ phosphatase. Cancer Cell 18 641. PMID: 21156286.

Pal et al (2010) Role of a novel coiled-coil domain-containing protein CCDC69 in regulating central spindle assembly. J Am Soc Nephrol 9 4117. PMID: 20962590.

Vázquez-Novelle and Petronczki (2010) Relocation of the chromosomal passenger complex prevents mitotic checkpoint engagement at anaphase. Curr Biol 20 1402. PMID: 20619651.

Xu et al (2010) VHL inactivation induces HEF1 and Aurora kinase A. J Cell Biol 21 2041. PMID: 20864688.

Platani et al (2009) The Nup107-160 nucleoporin complex promotes mitotic events via control of the localization state of the chromosome passenger complex. Mol Biol Cell 20 5260. PMID: 19864462.

Samoshkin et al (2009) Human condensin function is essential for centromeric chromatin assembly and proper sister kinetochore orientation. PLoS One 4 e6831. PMID: 19714251.

Scutt et al (2009) Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks. J Biol Chem 284 15880. PMID: 19359241.

Ganguly et al (2008) Cell cycle dependent degradation of MCAK: evidence against a role in anaphase chromosome movement. Toxins (Basel) 7 3187. PMID: 18843200.

Slawson et al (2008) A mitotic GlcNAcylation/phosphorylation signaling complex alters the posttranslational state of the cytoskeletal protein vimentin. Mol Biol Cell 19 4130. PMID: 18653473.

Vischioni et al (2006) Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther 5 2905. PMID: 17121938.

Do you know of a great paper that uses ZM 447439 from Tocris? If so please let us know.show all ▼show less ▲

View Related Products by Target

View Related Products by Product Action

Keywords: ZM 447439, supplier, inhibitors, inhibits, Aurora, kinases, B, Mitosis, ZM447439, AstraZeneca, Tocris Bioscience, Aurora Kinase Inhibitor products

Quick Order

Find multiple products by catalog number

divider line

Cancer Research Product Guide

Cancer Research Product Guide

Our Cancer Research Guide highlights over 750 products for cancer research. Request copy or view PDF today.

divider line

Kinase Inhibitor Toolbox

80 Kinase inhibitors
pre-dissolved in DMSO

Kinase Inhibitor Toolbox

Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.

divider line

Kinases Product Listing

Kinases Product Listing

Our Kinase listing highlights over 400 products for kinase research. Request copy or view PDF today.

divider line

Cell Cycle Life Science Poster

Cell Cycle & DNA Damage Repair Life Science Poster

Our Cell Cycle & DNA Damage Repair poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death. Request copy or view PDF today.

divider line

New Products in this Area

HS 38

ATP-competitive inhibitor of DAPK and ZIPK

st-Ht31 P

Negative control for st-Ht31 (Cat. No. 6286)

st-Ht31

Inhibits PKA/AKAP interactions; cell permeable

P21d hydrochloride

Potent and selective Brk inhibitor

CVT 313

cdk2 inhibitor

TPPB

High affinity PKC activator; also APP modulator

JH 295

Irreversible Nek2 inhibitor

OXSI 2

Potent Syk kinase inhibitor; also inhibits assembly of NLRP3 inflammasomes

STK16-IN-1

Serine/threonine protein kinase 16 (STK16) inhibitor; also inhibits PI 3Kδ, PI 3Kγ and mTOR kinases.

AZ PFKFB3 26

Potent and selective PFKFB3 inhibitor

NCL 00017509

Potent and reversible NIMA related kinase 2 (Nek2) inhibitor

XMD 8-87

Potent Ack1/TNK2 inhibitor

SKI 178

Non-lipid sphingosine kinase 1 (SphK1) inhibitor

ML 315 hydrochloride

Inhibitor of Clk and DYRK kinases

Everolimus

mTOR inhibitor;immunosuppressant

PKI (5-24)

High affinity PKA inhibitor

TDZD 8

Selective non-ATP competitive inhibitor of GSK 3β

BI 605906

Selective IKKβ inhibitor

GSK 319347A

Potent and selective IKKε inhibitor

FRAX 597

Potent group I PAK inhibitor

MRT 68921 dihydrochloride

Potent ULK inhibitor; inhibits autophagy

AM 2394

Potent glucokinase activator; orally bioavailable

eCF 309

Potent mTOR inhibitor

PF 3758309 dihydrochloride

Potent PAK4 inhibitor; orally available

AZ Dyrk1B 33

Potent and selective Dyrk1B kinase inhibitor

Sign-up for new product e-alerts
divider line

LinkedIn Updates

Follow Tocris on LinkedIn

Follow us on LinkedIn!

Visit our LinkedIn page for the latest Tocris news, events and updates.